Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis

• Published in: International journal of molecular sciences 2019-01, Vol.20 (3), p.552
• Main Authors: Dasilva-Freire, Noelia, Mayado, Andrea, Teodosio, Cristina, Jara-Acevedo, María, Álvarez-Twose, Iván, Matito, Almudena, Sánchez-Muñoz, Laura, Caldas, Carolina, Henriques, Ana, Muñoz-González, Javier I, García-Montero, Andrés C, Sánchez-Gallego, J Ignacio, Escribano, Luis, Orfao, Alberto
• Format: Article
• Language: English
• Subjects: antibody-targetable cell surface membrane proteins; Bone marrow; CD123 antigen; CD22 antigen; CD25 antigen; CD30 antigen; Cell surface; cell therapy and immunotherapy; Diagnostic systems; Disease; FDA approval; hematology; immuno-phenotyping; immunology; Immunotherapy; Kinases; Leukemia; Life span; Mast cell leukemia; Mastocytosis; Membrane proteins; Monoclonal antibodies; Mutation; Patients; Proteins; Quality of life; Regulatory agencies; systemic mastocytosis
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms20030552

Despite recent therapeutic advances, systemic mastocytosis (SM) remains an incurable disease due to limited complete remission (CR) rates even after novel therapies. To date, no study has evaluated the expression on SM bone marrow mast cells (BMMC) of large panel of cell surface suitable for antibody-targeted therapy. In this study, we analyzed the expression profile of six cell-surface proteins for which antibody-based therapies are available, on BMMC from 166 SM patients vs. 40 controls. Overall, variable patterns of expression for the markers evaluated were observed among SM BMMC. Thus, CD22, CD30, and CD123, while expressed on BMMC from patients within every subtype of SM, showed highly variable patterns with a significant fraction of negative cases among advanced SM (aggressive SM (ASM), ASM with an associated clonal non-MC lineage disease (ASM-AHN) and MC leukemia (MCL)), 36%, 46%, and 39%, respectively. In turn, CD25 and FcεRI were found to be expressed in most cases (89% and 92%) in virtually all BMMC (median: 92% and 95%) from both indolent and advanced SM, but with lower/absent levels in a significant fraction of MC leukemia (MCL) and both in MCL and well-differentiated SM (WDSM) patients, respectively. In contrast, CD33 was the only marker expressed on all BMMC from every SM patient. Thus, CD33 emerges as the best potentially targetable cell-surface membrane marker in SM, particularly in advanced SM.